Elevance Health, Inc. (ELV) fair value analysis
S&P 500 · Updated 2026-10-19
ELV price how computed
Forward Fair Value verdict
Fairly valuedELV is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $412.70
- Sector
- Healthcare
- 12-month range
- $280.74–$428.43
- Market cap
- $89.5B
- From 52-week high
- -3.7%
- Shares outstanding
- 217M
- Rank in Healthcare by discount to fair value
- #64 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Elevance Health, Inc. is a health insurance company that provides medical, dental, and vision insurance coverage to individuals and groups. The company operates across the United States through various insurance brands and serves customers in all 50 states.
ELV currently ranks #64 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $89.5B
- P/E (trailing)
- 14x
- Revenue (TTM)
- $201B
- Net margin
- 2.5%
- EPS (TTM)
- $29.39
- Gross margin
- 89.1%
- Debt / equity
- 0.69
- Revenue growth (3-yr avg)
- 5.9%
- Shares outstanding
- 217M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 61 · neutral
- 50-day average
- $403.84
- 200-day average
- $369.22
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $6.87 per share (4 payments)
- Yield on last price
- 1.66%
- Consecutive years of increases
- 14
- Last ex-dividend date
- 2026-09-10
- Last payment date
- 2026-09-25
Earnings how computed
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+20.6%)
2026-03 ▲ beat (+16.4%)
2025-12 ▲ beat (+7.8%)
2025-09 ▲ beat (+22.1%)
2025-06 ▼ miss (-0.9%)
2025-03 ▲ beat (+4.3%)
2024-12 ▼ miss (-0.3%)
2024-09 ▼ miss (-13.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 8 hold · 0 sell (22 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $452
- Target vs last price
- +9.5%
What our data shows for ELV
- Our model validated 17 trailing price-to-earnings windows for ELV, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $280.74–$428.43.
- The 14-day relative strength index sits at a neutral 61.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ELV
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ELV conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ELV stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ELV is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is ELV's TickrTrends verdict?
ELV's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does ELV compare to other Healthcare stocks?
ELV ranks #64 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ELV overbought or oversold?
ELV's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ELV pay a dividend?
Yes. ELV paid $6.87 per share over the last twelve months (4 payments), a 1.66% yield on TickrTrends' last price, and has raised the annual total for 14 consecutive years. The last ex-dividend date was 2026-09-10.
Does ELV usually beat earnings estimates?
Over its last 8 reported quarters ELV beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ELV?
Of 22 analysts covering ELV, 14 rate it a buy, 8 a hold and 0 a sell - buy-leaning, with a consensus price target of $452 (+9.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ELV vs A · ELV vs AVAH · ELV vs BVS · ELV vs CVS · ELV vs INMD